Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 18, 2017
Pharmacy Choice - Pharmaceutical News - FDA: Kalydeco Now Approved to Treat 33 Cystic Fibrosis Mutations - August 18, 2017

Pharmacy News Article

 5/17/17 - FDA: Kalydeco Now Approved to Treat 33 Cystic Fibrosis Mutations

The FDA has expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. According to an agency press release, the approval triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations, to 33.

The agency based its decision, in part, on the results of laboratory testing, which it used in conjunction with evidence from earlier human clinical trials. The approach provides a pathway for adding additional, rare mutations of the disease, based on laboratory data.

Many rare cystic fibrosis mutations have such small patient populations that clinical trial studies are not feasible, said Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research. This challenge led us to using an alternative approach based on precision medicine, which made it possible to identify certain gene mutations that are likely to respond to Kalydeco.

Results from an in vitro cell-based model system have been shown to reasonably predict clinical response to Kalydeco. When additional mutations responded to Kalydeco in the laboratory test, researchers were thus able to extrapolate clinical benefit demonstrated in earlier clinical trials of other mutations. This resulted in the addition of gene mutations for which the drug is now indicated.

Kalydeco, available as tablets or oral granules taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of cystic fibrosis, including weight gain. If the patient's genotype is unknown, an FDA-cleared cystic fibrosis mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

The expanded indication will affect another 3% of the cystic fibrosis population, impacting approximately 900 patients. Kalydeco serves as an example of how successful patient-focused drug development can provide greater understanding about a disease. For example, the Cystic Fibrosis Foundation maintains a 28,000-patient registry, including genetic data, which it makes available for research.



Copyright © 2017 Allied Media. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Aug 21: An Integrative Approach to Managing Arthritis
Aug 22: Men's Health
Aug 23: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Aug 24: Treatment of Parkinson's Disease and Comorbid Conditions
Aug 25: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415